The Lancet has NOT endorsed Covaxin. It has just published the phase I data -the preprint (non peer reviewed version) of which was available since last year. Good that @BharatBiotech published this data, but it does not mean it has a been cleared from the safety perspective.
Safety clearance requires testing in many many people of various groups. In this paper, 3 types different vaccines were tested in 100 people each and compared with 75 people of placebo.
As per @pfizer, more than 18,000 people were enrolled in the safety studies and compared with an equal amount of placebo administration. And in total, 21,720 took the Pfizer vaccine. This data is also public and published. These are some of the standards vaccine companies follow
• • •
Missing some Tweet in this thread? You can try to
force a refresh
